Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): Review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 429-434

  Vikelis, Michail ^a   Mitsikostas, Dimos D ^b   Rapoport, Alan M ^c  

^a Glyfada Headache Center   (Greece)

^b ATHENS NAVAL HOSPITAL   (Greece)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Iontophoretic patch; Migraine; Migraine treatment; Sumatriptan; Transdermal patch

Indexed keywords

NP 101; PLACEBO; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG; ZELRIX;

ANALGESIA; APPLICATION SITE REACTION; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; PHONOPHOBIA; PHOTOPHOBIA; REVIEW; SINGLE DRUG DOSE; SKIN ALLERGY; TRANSDERMAL PATCH; TREATMENT DURATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG INDUCED HEADACHE; ELECTRIC POTENTIAL; FIRST PASS EFFECT; INJECTION SITE IRRITATION; INJECTION SITE PARESTHESIA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; IONTOPHORESIS; MICROPROCESSOR; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; STOMACH MOTILITY; STOMACH PARESIS; TREATMENT OUTCOME;

EID: 84867024761     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s27456     Document Type: Review

References (21)

1. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995;35(7):387-396.
2. Stovner Lj, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193-210.
3. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160.
4. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol. 2000;57(3):418-420.
5. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache. 2008;48(4):553-563.
6. Hawkins K, Wang S, Rupnow MF. Indirect cost burden of migraine in the United States. J Occup Environ Med. 2007;49(4):368-374.
7. Vikelis M, Rapoport AM. New drug delivery options for migraine. Expert Rev Neurother. 2011;11(6):771-773.
8. Kelman L, Tanis D. The relationship between migraine pain and other associated symptoms. Cephalalgia. 2006;26(5):548-553.
9. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55(1):19-26.
10. Burstein R, Levy D, Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol (Paris). 2005;161(6-7):658-660.
11. Fuseau E, Petricoul O, Moore KHP, Barrow A, Ibbotson T. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet. 2002;41(11):801-811.
12. Uemura N, Onishi T, Mitaniyama A, et al. Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Investig. 2005;25(3):199-208.
13. Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs. 2010;24(11):929-940.
14. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf. 2003;2(2):123-132.
15. Pierce MW. Headache relief. Drug Discovery and Development. [internet]. March 1, 2008. Available from: http://www.dddmag.com/Article-Anti-migraine-Drugs-Feature-New-Delivery-Methods.aspx. Accessed May 11, 2012.
16. Siegel SJ, O'Neill C, Dubé LM, et al. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan succinate. Pharm Res. 2007;24(10):1919-1926.
17. Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T. Zelrix: a novel transdermal formulation of sumatriptan. Headache. 2009;49(6):817-825.
18. Goldstein J, Pugach N, Smith T, et al. Acute anti-migraine efficacy and tolerability of Zelrix, a novel iontophoretic transdermal patch of sumatriptan. Research abstract presented at 14th International Headache Congress; September 10-13, 2009. Philadelphia (PA). Headache. 2010;50(3):509-515.
19. Goldstein J, Pugach N, Smith TR. Acute anti-migraine efficacy and tolerability of Zelrix, a novel iontophoretic transdermal patch of sumatriptan. Cephalalgia 2009;29(Suppl 1):20.
20. Goldstein J, Smith TR, Pugach N, et al. A Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. [epub ahead of print].
21. Smith T, Pierce MW, Griesser J, et al. Long-term safety and efficacy of NP101, a sumatriptan iontophoretic patch for the treatment of acute migraine. Headache 2012;52:612-624.